| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H6N2S3 |
| Molecular Weight | 226.342 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(SSC1=S)C2=CN=CC=N2
InChI
InChIKey=CKNAQFVBEHDJQV-UHFFFAOYSA-N
InChI=1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3
Oltipraz is an organosulfur compound belonging to the dithiolethione class. It acts as a schistosomicide and has been shown in rodent models to inhibit the formation of cancers in the bladder, blood, colon, kidney, liver, lung, pancreas, stomach, and trachea, skin, and mammary tissue. Oltipraz and other 1,2-dithiole-3-thiones inactivate protein tyrosine phosphatases under physiologically-relevant conditions. Clinical trials of oltipraz have failed to demonstrate efficacy and have shown significant side effects, including neurotoxicity and gastrointestinal toxicity.
Originator
Approval Year
Cmax
Sourcing
PubMed
Patents
Sample Use Guides
HEK293 and hPTCs were plated in a 96-well configuration. Cells were incubated overnight at 37◦C in a humidified incubator with an atmosphere of 5% CO2 prior to treatment. The cell treatments consisted of 1) 0.1% vehicle control (DMSO), 2) cisplatin at 0, 50,80 mkM doses, 3) Nrf2 activator [sulforaphane(5 mkM), oleanolic acid (5 mkM), or oltipraz (12 mkM)], or 4) cisplatin(at the above doses) combined with a Nrf2 activator at specified doses. Cells were incubated with Nrf2 activators for 12, 24, or 48 h beginning either 3 h prior to cisplatin or 3 h after initiation of cis-platin exposure. After the specified incubation time, MTT reagent(2 mg/mL) (Sigma Aldrich) in DMEM or EpiCM containing no FBS was added and cells were incubated for 4 h at 37◦C. MTT reagent was removed after the 4 h incubation period, MTT solubility solution (2% HCl, 25% H2O, 73% 2-propanol) was added and cell viability was analyzed at 550 nm by VersaMax microreader plate (MolecularDevices, Sunnyvale, CA).
ACTIVE MOIETY
METABOLITE (PARENT)
